Thinly traded micro cap Edge Therapeutics (EDGE +5.5%) moves up in early trading, albeit on only 16K shares, on the heels of its announcement that results from its Phase 1/2 study, NEWTON, assessing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback